Skip to main content

Table 2 Laboratory variables of participants by treatment allocation to ferric carboxymaltose or iron sucrose

From: Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

 

Ferric carboxymaltose n = 22

Iron sucrose n = 20

P

Hemoglobin (g/L)

111 ± 9

115 ± 10

0.14

Iron (μmol/L)

14.0 (11.0–16.0)

10.5 (8.5–17.5)

0.31

Ferritin (μg/L)

211 ± 133

187 ± 130

0.55

Transferrin Saturation (%)

29 ± 9

27 ± 12

0.64

Transferrin (g/L)

2.2 ± 0.4

2.2 ± 0.5

0.65

Hepcidin (ng/mL)

7.8 (2.7–12.6)

3.4 (2.7–8.8)

0.24

iFGF23 (pg/mL)

843 (313–1922)

381 (245–1526)

0.33

cFGF23 (RU/mL)

704 (475–1204)

710 (448–1548)

0.76

PTH (pmol/L)

40.0 (20.6–68.3)

31.2 (16.6–42.2)

0.22

Ca (corrected) (mmol/L)

2.30 ± 0.17

2.31 ± 0.15

0.90

PO4 (mmol/L)

1.53 ± 0.44

1.42 ± 0.44

0.41

Albumin (g/L)

35.5 ± 2.5

34.6 ± 2.8

0.27

CRP (mg/L)

4.5 (2.0–6.0)

3.0 (2.0–5.0)

0.33

  1. RU/mL relative units per mL, CRP C-reactive protein